What Can We Expect From Neurotrope (NTRP) After Maxim Group’s Latest Coverage?

May 17, 2018 - By Margaret Downey

Neurotrope, Inc. (NASDAQ:NTRP) Logo

Why Has Maxim Group Given Neurotrope (NTRP) a $16.0000 Price Target

The broker Maxim Group has today has begun coverage on Neurotrope (NTRP) shares, with a Buy rating, while setting the PT at $16.0000.

The stock increased 2.57% or $0.23 during the last trading session, reaching $9.18. About 70,700 shares traded or 175.03% up from the average. Neurotrope, Inc. (NTRP) has 0.00% since May 18, 2017 and is . It has underperformed by 11.55% the S&P500.

Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease . The company has market cap of $72.59 million. The Company’s lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. It currently has negative earnings. The firm also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C.

Another recent and important Neurotrope, Inc. (NASDAQ:NTRP) news was published by Prnewswire.com which published an article titled: “Neurotrope, In Consultation With Leading Neuroscientists, Completes the Study Design for its Confirmatory Phase 2 …” on May 07, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: